Andrew Brodbelt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew Brodbelt has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Michael D. Jenkinson
Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom
9 shared publications - Abdurrahman I. Islim
The Walton Centre NHS Foundation Trust, Liverpool, UK
5 shared publications - Christopher Paul Millward
Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
5 shared publications - Conor Scott Gillespie
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
5 shared publications - George E. Richardson
University of Liverpool
5 shared publications - Mohammad A. Mustafa
School of Medicine, University of Liverpool, Liverpool, UK
5 shared publications
Latest Publications
- Open Access
- 9 April 2025
- Published by Elsevier in Cancer Epidemiology
- Vol. 97, 102811
Adult glioblastoma in England: Incidence, treatment, and outcomes with novel population-based strata
- 9 April 2025
- Published by Elsevier in Cancer Epidemiology
- Vol. 97, 102811
Open AccessAdult glioblastoma in England: Incidence, treatment, and outcomes with novel population-based strata
- Open Access
- 7 February 2024
- Published by Springer Nature in Genome Biology
- Vol. 25 (1) , 1-29
IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy
Background: Glioblastoma (GBM) brain tumors lackingIDH1mutations (IDHwt) have the worst prognosis of all brain neoplasms. Patients receive surgery and chemoradiotherapy but tumors almost always fatally recur.Results: Using RNA sequencing data from 107 pairs of pre- and post-standard treatment locally recurrent IDHwt GBM tumors, we identify two responder subtypes based on longitudinal changes in gene expression. In two thirds of patients, a specific subset of genes is upregulated from primary to recurrence (Up responders), and in one third, the same genes are downregulated (Down responders), specifically in neoplastic cells. Characterization of the responder subtypes indicates subtype-specific adaptive treatment resistance mechanisms that are associated with distinct changes in the tumor microenvironment. In Up responders, recurrent tumors are enriched in quiescent proneural GBM stem cells and differentiated neoplastic cells, with increased interaction with the surrounding normal brain and neurotransmitter signaling, whereas Down responders commonly undergo mesenchymal transition. ChIP-sequencing data from longitudinal GBM tumors suggests that the observed transcriptional reprogramming could be driven by Polycomb-based chromatin remodeling rather than DNA methylation.Conclusions: We show that the responder subtype is cancer-cell intrinsic, recapitulated in in vitro GBM cell models, and influenced by the presence of the tumor microenvironment. Stratifying GBM tumors by responder subtype may lead to more effective treatment.
- 7 February 2024
- Published by Springer Nature in Genome Biology
- Vol. 25 (1) , 1-29
Open AccessIDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy
Background: Glioblastoma (GBM) brain tumors lackingIDH1mutations (IDHwt) have the worst prognosis of all brain neoplasms. Patients receive surgery and chemoradiotherapy but tumors almost always fatally recur.Results: Using RNA sequencing data from 107 pairs of pre- and post-standard treatment locally recurrent IDHwt GBM tumors, we identify two responder subtypes based on longitudinal changes in gene expression. In two thirds of patients, a specific subset of genes is upregulated from primary to recurrence (Up responders), and in one third, the same genes are downregulated (Down responders), specifically in neoplastic cells. Characterization of the responder subtypes indicates subtype-specific adaptive treatment resistance mechanisms that are associated with distinct changes in the tumor microenvironment. In Up responders, recurrent tumors are enriched in quiescent proneural GBM stem cells and differentiated neoplastic cells, with increased interaction with the surrounding normal brain and neurotransmitter signaling, whereas Down responders commonly undergo mesenchymal transition. ChIP-sequencing data from longitudinal GBM tumors suggests that the observed transcriptional reprogramming could be driven by Polycomb-based chromatin remodeling rather than DNA methylation.Conclusions: We show that the responder subtype is cancer-cell intrinsic, recapitulated in in vitro GBM cell models, and influenced by the presence of the tumor microenvironment. Stratifying GBM tumors by responder subtype may lead to more effective treatment.
- Open Access
- 16 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , iii8
QUANTIFYING THE NEED FOR A BEST SUPPORTIVE CARE CLINIC
Patients newly diagnosed with high-grade primary brain tumour and poor performance status discussed in the Multidisciplinary team (MDT) may not be felt to benefit from active treatment and their uptake in clinic is poor. We aimed to explore the volume of patients not being treated in our region, their survival rates, and the reasons for the limited requests for clinical review. Data was obtained from medical records of identified patients from April 2021 to April 2022. This included demographics, presentation, diagnosis date, clinic visits, and date of death. 78 patients were referred for suspected high-grade primary brain tumours and selected for best supportive care by the MDT. Only 73 (64% male) were diagnosed radiologically with a high-grade primary tumour and the rest were excluded. Median age was 79 years (range 74 – 84). The commonest presenting symptoms were confusion (53%), falls (29%), and dysphasia (25%). Median survival time after diagnostic scan was 67 days (range 34 – 107). Survival rates at 1, 3, 6, and 12 months were 82%, 33%, 8%, and 1%, respectively. 28 patients (38%) were seen in clinic. 13 had been provided with the option to attend by letter. The median duration from referral to clinic was 9 days (range 7 – 14). Only a third of non-treatable patients with newly diagnosed high-grade primary brain tumours are being seen in the clinic. Communication between the MDT and the patient offering this service is poor. Longer term survivors suggest an incorrect diagnosis who may benefit from further review.
- 16 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , iii8
Open AccessQUANTIFYING THE NEED FOR A BEST SUPPORTIVE CARE CLINIC
Patients newly diagnosed with high-grade primary brain tumour and poor performance status discussed in the Multidisciplinary team (MDT) may not be felt to benefit from active treatment and their uptake in clinic is poor. We aimed to explore the volume of patients not being treated in our region, their survival rates, and the reasons for the limited requests for clinical review. Data was obtained from medical records of identified patients from April 2021 to April 2022. This included demographics, presentation, diagnosis date, clinic visits, and date of death. 78 patients were referred for suspected high-grade primary brain tumours and selected for best supportive care by the MDT. Only 73 (64% male) were diagnosed radiologically with a high-grade primary tumour and the rest were excluded. Median age was 79 years (range 74 – 84). The commonest presenting symptoms were confusion (53%), falls (29%), and dysphasia (25%). Median survival time after diagnostic scan was 67 days (range 34 – 107). Survival rates at 1, 3, 6, and 12 months were 82%, 33%, 8%, and 1%, respectively. 28 patients (38%) were seen in clinic. 13 had been provided with the option to attend by letter. The median duration from referral to clinic was 9 days (range 7 – 14). Only a third of non-treatable patients with newly diagnosed high-grade primary brain tumours are being seen in the clinic. Communication between the MDT and the patient offering this service is poor. Longer term survivors suggest an incorrect diagnosis who may benefit from further review.
- Open Access
- 21 July 2023
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 165 (10) , 2923
Correction to: Cranial meningioma with bone involvement: surgical strategies and clinical considerations
- 21 July 2023
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 165 (10) , 2923
Open AccessCorrection to: Cranial meningioma with bone involvement: surgical strategies and clinical considerations
- Open Access
- 2 June 2023
- Published by Taylor & Francis in British Journal Of Neurosurgery
- p. 1-11
Health-related quality of life following cranioplasty – a systematic review
Cranioplasty is a neurosurgical procedure that repairs a defect in the skull Coupled with the underlying pathology cranioplasty associated morbidity can have a large impact on patient quality of life, which is often poorly explored. The objective of this systematic review was to identify patient-reported outcomes evaluating health-related quality of life following cranioplasty. The review protocol was registered on PROSPERO (CRD42021251543) and a systematic review was conducted in accordance with the PRISMA statement. PubMed, Embase, CINAHL Plus, and the Cochrane databases were searched from inception to 1 May 2022. All studies reporting HRQoL following cranioplasty were included. Reporting was assessed using the ISOQOL checklist and risk of bias was assessed using the Newcastle-Ottawa Scale or the Johanna-Briggs Institute Scale, as appropriate. A total of 25 studies were included of which 20 were cross-sectional and 2 longitudinal. Most studies utilized study specific questionnaires and Likert scales to assess HRQoL. The studies found a significant improvement in physical functioning, social functioning, cosmetic outcome, and overall HRQoL following cranioplasty. Further longitudinal studies utilising validated measurement tools are required to better understand the effect of cranioplasty at a patient level.
- 2 June 2023
- Published by Taylor & Francis in British Journal Of Neurosurgery
- p. 1-11
Open AccessHealth-related quality of life following cranioplasty – a systematic review
Cranioplasty is a neurosurgical procedure that repairs a defect in the skull Coupled with the underlying pathology cranioplasty associated morbidity can have a large impact on patient quality of life, which is often poorly explored. The objective of this systematic review was to identify patient-reported outcomes evaluating health-related quality of life following cranioplasty. The review protocol was registered on PROSPERO (CRD42021251543) and a systematic review was conducted in accordance with the PRISMA statement. PubMed, Embase, CINAHL Plus, and the Cochrane databases were searched from inception to 1 May 2022. All studies reporting HRQoL following cranioplasty were included. Reporting was assessed using the ISOQOL checklist and risk of bias was assessed using the Newcastle-Ottawa Scale or the Johanna-Briggs Institute Scale, as appropriate. A total of 25 studies were included of which 20 were cross-sectional and 2 longitudinal. Most studies utilized study specific questionnaires and Likert scales to assess HRQoL. The studies found a significant improvement in physical functioning, social functioning, cosmetic outcome, and overall HRQoL following cranioplasty. Further longitudinal studies utilising validated measurement tools are required to better understand the effect of cranioplasty at a patient level.
- Open Access
- 6 March 2023
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 165 (5) , 1355-1363
Cranial meningioma with bone involvement: surgical strategies and clinical considerations
Background: Intracranial meningioma with bone involvement and primary intraosseous meningioma is uncommon. There is currently no consensus for optimal management. This study aimed to describe the management strategy and outcomes for a 10-year illustrative cohort, and propose an algorithm to aid clinicians in selecting cranioplasty material in such patients. Methods: A single-centre, retrospective cohort study (January 2010–August 2021). All adult patients requiring cranial reconstruction due to meningioma with bone involvement or primary intraosseous meningioma were included. Baseline patient and meningioma characteristics, surgical strategy, and surgical morbidity were examined. Descriptive statistics were performed using SPSS v24.0. Data visualisation was performed using R v4.1.0. Results: Thirty-three patients were identified (mean age 56 years; SD 15) There were 19 females. Twenty-nine patients had secondary bone involvement (88%). Four had primary intraosseous meningioma (12%). Nineteen had gross total resection (GTR; 58%). Thirty had primary ‘on-table’ cranioplasty (91%). Cranioplasty materials included pre-fabricated polymethyl methacrylate (pPMMA) (n = 12; 36%), titanium mesh (n = 10; 30%), hand-moulded polymethyl methacrylate cement (hPMMA) (n = 4; 12%), pre-fabricated titanium plate (n = 4; 12%), hydroxyapatite (n = 2; 6%), and a single case combining titanium mesh with hPMMA cement (n = 1; 3%). Five patients required reoperation for a postoperative complication (15%). Conclusion: Meningioma with bone involvement and primary intraosseous meningioma often requires cranial reconstruction, but this may not be evident prior to surgical resection. Our experience demonstrates that a wide variety of materials have been used successfully, but that pre-fabricated materials may be associated with fewer postoperative complications. Further research within this population is warranted to identify the most appropriate operative strategy.
- 6 March 2023
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 165 (5) , 1355-1363
Open AccessCranial meningioma with bone involvement: surgical strategies and clinical considerations
Background: Intracranial meningioma with bone involvement and primary intraosseous meningioma is uncommon. There is currently no consensus for optimal management. This study aimed to describe the management strategy and outcomes for a 10-year illustrative cohort, and propose an algorithm to aid clinicians in selecting cranioplasty material in such patients. Methods: A single-centre, retrospective cohort study (January 2010–August 2021). All adult patients requiring cranial reconstruction due to meningioma with bone involvement or primary intraosseous meningioma were included. Baseline patient and meningioma characteristics, surgical strategy, and surgical morbidity were examined. Descriptive statistics were performed using SPSS v24.0. Data visualisation was performed using R v4.1.0. Results: Thirty-three patients were identified (mean age 56 years; SD 15) There were 19 females. Twenty-nine patients had secondary bone involvement (88%). Four had primary intraosseous meningioma (12%). Nineteen had gross total resection (GTR; 58%). Thirty had primary ‘on-table’ cranioplasty (91%). Cranioplasty materials included pre-fabricated polymethyl methacrylate (pPMMA) (n = 12; 36%), titanium mesh (n = 10; 30%), hand-moulded polymethyl methacrylate cement (hPMMA) (n = 4; 12%), pre-fabricated titanium plate (n = 4; 12%), hydroxyapatite (n = 2; 6%), and a single case combining titanium mesh with hPMMA cement (n = 1; 3%). Five patients required reoperation for a postoperative complication (15%). Conclusion: Meningioma with bone involvement and primary intraosseous meningioma often requires cranial reconstruction, but this may not be evident prior to surgical resection. Our experience demonstrates that a wide variety of materials have been used successfully, but that pre-fabricated materials may be associated with fewer postoperative complications. Further research within this population is warranted to identify the most appropriate operative strategy.
- Open Access
- 4 May 2022
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 36 (3) , 385-393
Cranioplasty with hydroxyapatite or acrylic is associated with a reduced risk of all-cause and infection-associated explantation
Cranioplasty remains an essential procedure following craniectomy but is associated with high morbidity. We investigated factors associated with outcomes following first alloplastic cranioplasty.A ...
- 4 May 2022
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 36 (3) , 385-393
Open AccessCranioplasty with hydroxyapatite or acrylic is associated with a reduced risk of all-cause and infection-associated explantation
Cranioplasty remains an essential procedure following craniectomy but is associated with high morbidity. We investigated factors associated with outcomes following first alloplastic cranioplasty.A ...
- 24 February 2022
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 36 (6) , 770-776
Tumour treating fields in glioblastoma: is the treatment tolerable, effective, and practical in UK patients?
Tumour Treating Fields (TTF) in combination with standard therapy, prolongs survival in patients with glioblastoma (GBM). The aim of the current study was to assess the feasibility of integrating T...
- 24 February 2022
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 36 (6) , 770-776
Tumour treating fields in glioblastoma: is the treatment tolerable, effective, and practical in UK patients?
Tumour Treating Fields (TTF) in combination with standard therapy, prolongs survival in patients with glioblastoma (GBM). The aim of the current study was to assess the feasibility of integrating T...
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S44-S45
A retrospective review of the clinical outcomes of lung cancer patients referred into the Regional Neuro-Oncology Pathway in 2020 in Merseyside, United Kingdom
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S44-S45
A retrospective review of the clinical outcomes of lung cancer patients referred into the Regional Neuro-Oncology Pathway in 2020 in Merseyside, United Kingdom
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S3-S4
A retrospective review of the management of lung cancer patients referred into the regional neuro-oncology pathway in Merseyside, United Kingdom
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S3-S4
A retrospective review of the management of lung cancer patients referred into the regional neuro-oncology pathway in Merseyside, United Kingdom